These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 24280959)
1. Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Chimenti MS; Teoli M; Saraceno R; Dattola A; Ventura A; Chiricozzi A; Chiaramonte C; Perricone R; Chimenti S Dermatology; 2013; 227(4):305-10. PubMed ID: 24280959 [TBL] [Abstract][Full Text] [Related]
2. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483 [TBL] [Abstract][Full Text] [Related]
3. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944 [TBL] [Abstract][Full Text] [Related]
4. Golimumab for the treatment of psoriatic arthritis. Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657 [TBL] [Abstract][Full Text] [Related]
5. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Oldfield V; Plosker GL BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653 [TBL] [Abstract][Full Text] [Related]
6. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299 [TBL] [Abstract][Full Text] [Related]
7. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309 [TBL] [Abstract][Full Text] [Related]
8. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions. Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546 [TBL] [Abstract][Full Text] [Related]
15. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU; Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810 [TBL] [Abstract][Full Text] [Related]
16. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). Kavanaugh A; Mease P J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603 [TBL] [Abstract][Full Text] [Related]
17. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor. Boyce EG; Halilovic J; Stan-Ugbene O Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591 [TBL] [Abstract][Full Text] [Related]
18. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A; Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701 [TBL] [Abstract][Full Text] [Related]
19. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566 [TBL] [Abstract][Full Text] [Related]
20. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]